Matthew Angel - 24 Mar 2026 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)

Reporting relationship: CEO and President, Director, 10%+ Owner
Issuer ticker: TPST
Reported as of: 24 Mar 2026
Net transaction value: +$500,001
SEC form: 4
Accepted by SEC: 23 Jun 2026, 16:56:17 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Angel

Key filing fact

Matthew Angel filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 23 Jun 2026.

Key facts

This page summarizes Matthew Angel's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 16:56.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: +$500,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001931356 Primary reporting owner

Angel Matthew

Relationship: CEO and President, Director, 10%+ Owner
Address: C/O TEMPEST THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE
Signature: /s/ Matthew Angel
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TPST transaction

Common Stock

Purchase

Transaction value: $500,001
Shares: +231,482
Change %
Price: $2.16
Shares after: 231,482
Date: 24 Mar 2026
Ownership: By Factor Bioscience Inc.
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TPST transaction Derivative

Series A Warrant (right to buy)

Purchase

Transaction value
Shares: +231,482
Change %
Price
Shares after: 231,482
Date: 24 Mar 2026
Ownership: By Factor Bioscience Inc.
Underlying class: Common Stock
Underlying amount: 231,482
Exercise price: $2.16
Footnotes: F1, F2, F3, F4

TPST transaction Derivative

Series B Warrant (right to buy)

Purchase

Transaction value
Shares: +231,482
Change %
Price
Shares after: 231,482
Date: 24 Mar 2026
Ownership: By Factor Bioscience Inc.
Underlying class: Common Stock
Underlying amount: 231,482
Exercise price: $2.16
Footnotes: F1, F2, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

Footnote F2

The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

Footnote F3

The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

Footnote F4

The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.

Footnote F5

The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.

SEC remarks

This transaction is being reported late due to an inadvertent administrative oversight.